Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 10/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26997341 | 0.87 | TMEM97 (0.34) | PDE2ATMEM97SIGMAR1NLRP3POLB | |
| SCHEMBL26997338 | 0.84 | LMNA (0.36) | PDE2ATMEM97SIGMAR1NLRP3 | |
| SCHEMBL22357753 | 0.83 | HTR1D (0.43) | PDE2ATMEM97SIGMAR1NLRP3 | |
| SCHEMBL22357752 | 0.81 | HTR1D (0.40) | PDE2ATMEM97SIGMAR1NLRP3SYK | |
| SCHEMBL20117051 | 0.81 | SYK (0.36) | NLRP3POLBSYKALDH1A1HSD17B10 | |
| SCHEMBL22357755 | 0.79 | MTNR1A (0.37) | NLRP3POLBALDH1A1HPGDHSD17B10 | |
| SCHEMBL6112453 | 0.75 | POLB (0.47) | POLB | |
| SCHEMBL23218320 | 0.71 | NLRP3 (0.42) | NLRP3DNMT1POLB | |
| SCHEMBL26121564 | 0.70 | RET (0.33) | NLRP3 | |
| SCHEMBL20116951 | 0.69 | CMKLR1 (0.35) | PDE2ANLRP3POLBCASRSSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | PDE2A 453/4885TMEM97 2140/4885SIGMAR1 1839/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | PDE2A 453/4885TMEM97 2140/4885SIGMAR1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.